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Abstract: Streptococcus canis is a common colonizing bacterium of the urogenital tract of cats and
dogs that can also cause invasive disease in these animal populations and in humans. Although the
virulence mechanisms of S. canis are not well-characterized, an M-like protein, SCM, has recently
identified been as a potential virulence factor. SCM is a surface-associated protein that binds to host
plasminogen and IgGs suggesting its possible importance in host-pathogen interactions. In this
study, we developed in vitro and ex vivo blood component models and murine models of S. canis
vaginal colonization, systemic infection, and dermal infection to compare the virulence potential of
the zoonotic S. canis vaginal isolate G361 and its isogenic SCM-deficient mutant (G361∆scm). We
found that while S. canis establishes vaginal colonization and causes invasive disease in vivo, the
contribution of the SCM protein to virulence phenotypes in these models is modest. We conclude
that SCM is dispensable for invasive disease in murine models and for resistance to human blood
components ex vivo, but may contribute to mucosal persistence, highlighting a potential contribution
to the recently appreciated genetic diversity of SCM across strains and hosts.
Keywords: Streptococcus canis; M protein; virulence factor; innate immunity; vaginal colonization
1. Introduction
Streptococcus canis is a Gram-positive beta-hemolytic group G Streptococcus that col-
onizes the epithelial, respiratory, gastrointestinal, and urogenital surfaces of cats and
dogs [1–3]. Officially named a species in 1986, S. canis is well-recognized in veterinary
medicine for causing a variety of invasive diseases across domestic animal species including
sepsis, necrotizing fasciitis, urinary tract infection, ulcerative keratitis, and mastitis [4–9].
Similar S. canis colonization and disease manifestations have been reported in wild animal
populations [10–12]. Since its first description as a zoonotic agent in 1996 [13], human cases
of S. canis-mediated endocarditis, septicemia, cellulitis, and periprosthetic joint infection
have been reported [14–21]. A retrospective study identified S. canis as the causative agent
in ~1% of human streptococcal infections, however, given the reliance of Lancefield classi-
fication for group G Streptococcus identification without further speciation, coupled with
close interactions between humans and companion animals, it is likely that S. canis human
infections are underestimated [22,23].
The genetic diversity and molecular pathogenesis of S. canis is being actively explored.
There are currently more than 50 multi-locus sequence types (MLST) and 20 genomes for
S. canis [23,24]. The host immune response to S. canis is not well-described, yet the pyogenic
nature of many S. canis soft tissue infections suggest neutrophils and macrophages may
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be involved. To date, knowledge of S. canis virulence factors remains limited, and is
largely extrapolated from genetic similarities to the widely-studied group A Streptococcus
(S. pyogenes) [12]. Similar to S. pyogenes, S. canis possesses an arginine deiminase system [25],
a streptolysin O orthologue [26], lysogenic bacteriophage [27], and an M-like protein termed
SCM (or SPASc) [28], which is currently the best characterized among candidate S. canis
virulence factors [29].
In S. pyogenes, the M protein, which is genetically diverse with more than 200 emm
types, serves multiple roles in pathogenesis and immune evasion [30]. Likewise, S. canis
SCM displays genetic heterogeneity. There are currently 15 SCM types divided into group I
and II alleles [23]. SCM is a fibrillar surface protein [26] which binds plasminogen [29] and
the Fc region of IgGs from multiple species including human, dog, cat, and mouse [31]. We
recently demonstrated that SCM self-interactions facilitate bacterial aggregation and that
SCM interactions with IgG initiate formation of protein complexes in human plasma [32].
However, the contribution of SCM, and impact of its allelic variability, to S. canis coloniza-
tion and virulence remains undefined.
In this study, we incorporated in vitro and ex vivo human blood component models,
together with murine models of S. canis vaginal colonization, systemic infection, and dermal
infection to broadly characterize the virulence potential of the zoonotic S. canis vaginal
isolate G361, originally isolated from a 40-year-old female, and its isogenic SCM-deficient
mutant (G361∆scm).
2. Materials and Methods
2.1. Bacterial Strains, Growth Conditions, and In Vitro Phenotyping Assays
Bacterial strains used in this study include Streptococcus canis human vaginal wild-
type (WT) isolate G361 [33] and isogenic scm-targeted insertional mutant G361∆scm [32],
Streptococcus pyogenes human invasive isolate 5448 M1 and isogenic ∆emm1 [34], and
Streptococcus agalactiae human meningeal isolate COH1 (ATCC BAA-1176). All bacterial
strains were grown to stationary phase in Todd-Hewitt broth (THB, Hardy Diagnostics),
or THB agar plates, at 37 ◦C without shaking. Erythromycin (5 µg/mL) was added to
G361∆scm to retain the plasmid insertion. Cultures were diluted in fresh THB and incu-
bated at 37 ◦C until mid-logarithmic phase (defined as OD600 = 0.4). For growth curves,
stationary cultures were diluted to OD600 = 0.1 in either fresh THB or RPMI-1640 (Gibco)
and incubated at 37 ◦C for 3 h with optical density measured every 30 min. To assess
hemolytic activity, WT G361 and G361∆scm were grown overnight and 10 µL was spot-
ted onto blood agar plates (TSA with 5% sheep blood, Thermo Scientific) and incubated
for 24 h at 37 ◦C with 5% CO2. For minimum inhibitory concentrations (MIC), mid-log
phase S. canis was diluted 1:100 in THB and 100 µL was added to 96-well microtiter plates.
Hydrogen peroxide or hypochlorite (1.5-fold dilution series, final concentrations tested
0–3.5 mM and 0–0.34 mM respectively) was diluted in THB and 100 µL was added to the
bacterial plates (200 µL total). The plates were then incubated at 37 ◦C for 18 h and OD600
was measured to determine MIC values (calculated as 90% reduction in OD600 from S. canis
only controls).
2.2. Biofilm Formation
S. canis and S. pyogenes biofilms were assessed using methods adapted from previous
work [35]. Briefly, stationary cultures were diluted in THB or RPMI-1640 to OD600 = 0.1,
and 200 µL added to tissue culture-treated 96-well plates. Biofilms were allowed to form
for 48 h at 37 ◦C without shaking. After washing 3X with PBS, biofilms were stained with
1µM SYTO 13 nucleic acid stain (Invitrogen) for 30 min in the dark. Biofilms were then
washed 3X with PBS and quantified by measuring fluorescence at OD485/OD520 on an
Infinite 200 Pro (Tecan) plate reader. Fluorescent images of biofilms were also collected
using an Echo Revolve microscope at 100X magnification.
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2.3. Mammalian Cell Lines and Growth Conditions
Canine macrophage-like cells (DH82), immortalized human vaginal epithelial cells
(VK2/E6E7), and human monocyte cell line (THP-1) were acquired from the American
Type Culture Collection (ATCC CRL-10389, ATCC CRL-2616, and ATCC TIB-202 respec-
tively). HEK-Blue IL-1β cells (Cat# hkb-il1b) were purchased from InvivoGen. DH82
cells were cultured in Eagle’s Minimum Essential Medium (EMEM) (Gibco) + 15% FBS
(heat inactivated). VK2 cells were cultured in keratinocyte serum-free medium (KSFM)
(Gibco) with 0.5 ng/mL human recombinant epidermal growth factor and 0.05 mg/mL
bovine pituitary extract. THP-1 cells were grown in suspension in the following media:
RPMI-1640 (Gibco) + 10% FBS (heat inactivated) + 10 mM HEPES + 1 mM sodium pyruvate
+ 4500 mg/L glucose + 1500 µg/mL sodium bicarbonate + 0.05 mM 2-mercaptoethanol.
When macrophage differentiation was necessary, the cells were treated for 24 h with 25 nM
phorbol myristate acetate (PMA) to produce an adherent culture. HEK-Blue IL-1β cells
were grown in adherent culture in Dulbecco’s Modified Eagle Medium (DMEM) with
L-glutamine (Gibco) + 10% FBS (heat inactivated) + 200 µg/mL HygromycinB (InvivoGen)
+ 100 µg/mL Zeocin (Invitrogen). All cells were cultured in a 37 ◦C incubator with 5% CO2.
Adherent cells were split every 3–4 days at ~80% confluency, and 0.25% trypsin/2.21mM
EDTA (Corning) were used to detach DH82 and VK2 cells for passaging. HEK-Blue IL-1β
indicator cells were detached with calcium- and magnesium-free sterile PBS.
2.4. Human Blood Collection and Neutrophil Purification
Under approval from UC San Diego and Cedars-Sinai Medical Center Institutional
Review Boards (Protocol # 131002), venous blood was obtained after informed consent from
healthy adult volunteers, with heparin as an anticoagulant for whole blood and neutrophil
studies. Neutrophils were isolated as described previously [36] using PolymorphPrep
(Axis-Shield) to create a density gradient by centrifugation according to the manufacturer’s
instructions.
2.5. Bacterial Killing Assays
Bacterial killing assays were modified from previous work [35–37]. For DH82 and
THP-1 killing assays, cells were plated in 96-well plates at 3 × 104 cells per well. THP-1
cells were differentiated to macrophages, as described above. The following day S. canis
was diluted in PBS and added to the macrophages at multiplicity of infection (MOI) = 1.
The culture plates were centrifuged for 5 min at 300× g to facilitate bacterial contact, and
then plates were incubated at 30 min at 37 ◦C in 5% CO2. At the end of incubation, the
supernatant was removed, and the macrophages were rinsed once with PBS before being
lysed with water, serially diluted, and plated on THB agar. For human neutrophil killing
assays, neutrophils were diluted to 2 × 106 cells/mL in RPMI-1640 and seeded at 2 × 105
cells/well in 96-well tissue culture plates. S. canis was diluted in RPMI-1640 was added to
neutrophils at MOI = 1. Plates were centrifuged at 300× g for 5 min to facilitate bacterial
contact with neutrophils, and then incubated at 37 ◦C in 5% CO2 for 30 min or 60 min.
Samples were lysed with water, serially diluted, and then plated on THB agar. For human
and murine whole-blood killing assays, 90 µL of whole blood (peripheral blood from
human venipuncture or murine cardiac puncture) and 10 µL containing 1 × 105 colony-
forming units (CFU) of S. canis were incubated at 37 ◦C with rotation for 30 min or 60 min,
and plated on THB agar. In all assays, S. canis survival was calculated as a percentage of
the inoculum.
2.6. Reactive Oxygen Species Assays
Induction of reactive oxygen species release from DH82 cells was adapted from
previous work [37]. Briefly, DH82 cells in confluent adherent culture were dissociated
and washed in calcium and magnesium-free HBSS. The cells were stained with 2′,7′-
dichlorofluorescein diacetate (Sigma Aldrich), seeded into 96-well culture plates, and
infected with S. canis at MOI = 10 suspended in HBSS with calcium and magnesium. Plates
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were incubated at 37 ◦C with 5% CO2 for 120 min, and every 20 min, fluorescence intensity
(485 nm excitation/530 nm emission) was measured using an EnSpire Multimode Plate
Reader (PerkinElmer). Samples were normalized to fold change of fluorescence signal of
time = 0.
2.7. IL-1β Induction Assays
Detection of THP-1 cell IL-1β release was measured as adapted from prior work [38].
HEK-Blue IL-1β reporter cells (50,000 cells per well in 96-well plates) were stimulated for
16 h at 37 ◦C in 5% CO2 with 50 µL of supernatants from THP-1 macrophages previously
infected with S. canis or S. pyogenes at MOI = 1 for 30 min. After 18 h, supernatants from the
HEK-Blue cells were analyzed for secreted alkaline phosphatase activity by the addition
of 50 µL of HEK-Blue supernatants onto 150 µL of Quanti-Blue reagent (Invivogen) and
monitoring the optical density at 620 nm via an EnSpire Multimode Plate Reader. Four
independent replicate experiments were performed, and data compiled and expressed as
relative units normalized to the mean optical density for the GAS group across all four
experiments.
2.8. Adherence Assays
Vaginal epithelial adherence assays were performed as adapted from prior meth-
ods [35,39]. VK2 cells were grown to confluency in 24-well tissue culture plates. Once
confluent, VK2 cells were infected with S. canis or S. agalactiae at MOI = 1 (assuming 1× 106
VK2 cells per well). Bacteria was brought into contact with the VK2 cells by centrifugation
for 1 min at 300× g. Cells were incubated at 37 ◦C in 5% CO2 for 30 min, supernatant was
removed, and cells washed 6X with sterile PBS. Cell layers were incubated for 5 min with
100 µL 0.25% trypsin/2.21mM EDTA after which 400 µL of 0.025% Triton-X in PBS was
added. Wells were mixed vigorously 30X to ensure detachment and lysis, and bacterial
recovery was determined by plating on THB agar. Data was expressed as a percentage of
adherent CFU compared to original inoculum.
2.9. Human Sera Titer Assays
For detection of human titers against SCM, a purified truncated form of SCM (KO-
173225) [31] which does not bind human IgG Fc, was immobilized on 96-well high-binding
microtiter plates (Corning Cat# 3361) at 1 µg/well via overnight incubation at RT. Wells
were washed 3X with PBS + 0.05% Tween 20 and blocked with 1X Reagent Diluent (from
R&D Systems, Cat#841380) for 1 h at RT. Twenty human serum samples were diluted
1:100, 1:1000, and 1:10,000 in Reagent and added at 100 uL/well. As a positive control,
recombinant human IgG (BioRad Cat# HCA192) was added at 0.5 ug, 5 ng, and 50 pg/well
in place of SCM protein. Negative controls included SCM-coated wells incubated with
Reagent Diluent. Diluted serum and controls were incubated for 2 h at 37 ◦C and washed 3X
with PBS + 0.05% Tween 20. Human serum binding was detected using a Goat anti-human
Ig AF488 (diluted to 1:500, Southern Biotech, Cat#2010-30) and incubated for 1 h at 37 ◦C
in the dark. Wells were washed 1X with PBS + 0.05% Tween 20 and 1X with PBS alone to
remove residual Tween 20. Fluorescence (485 nm excitation/530 nm emission) was detected
an EnSpire Multimode Plate Reader and data expressed at relative fluorescence units.
2.10. Animals
The UCSD Institutional Animal Care and Use Committee (Protocol #S00227M) ap-
proved all animal protocols and procedures. Wildtype (WT) CD-1 male and female mice
aged 8-10 weeks were purchased from Charles River Laboratories (strain code 022). Groups
were assigned randomly and housed at 5 animals per cage in separate cages. Mice were
allowed to eat and drink ad libitum.
Microorganisms 2021, 9, 183 5 of 16
2.11. In Vivo Intradermal Infection Model
For intradermal infection models adapted from prior work [30], CD1 male and female
mice (n = 20/group) were shaved 1 d prior to infection. On each flank, mice were injected
subcutaneously with 100 µL of PBS containing either 1 × 108 CFU WT S. canis strain G361
or ∆scm mutant. Sides receiving WT or ∆scm (left and right) were alternated at random
across groups of mice. Lesions were imaged daily for three days and surface area calculated
using ImageJ software.
2.12. In Vivo Sepsis Model
The UCSD Institutional Animal Care and Use Committee (Protocol #S00227M) ap-
proved the anticipated mortality and study design. For in vivo survival studies, CD-1 male
and female mice (n = 10/group) were intraperitoneally (i.p.) injected with 100 µL of PBS
containing 5 × 107 CFU wildtype GAS strain 5448, WT S. canis strain G361 or ∆scm mutant.
Mice were monitored three times daily for mortality. Analgesics were not administered
during systemic infection due to potential effects on the study outcome.
2.13. In Vivo Vaginal Colonization Model
For vaginal colonization models, CD1 females (n = 18/group in single challenge
experiments or n = 20 in competition experiments) were treated i.p. with 0.5 mg β-estradiol
in 100 µL sesame oil (5 mg/mL) to synchronize estrus as described previously [40]. After
24 h, mice were vaginally inoculated with 1 × 107 CFU WT GBS COH1, WT S. canis
strain G361 or ∆scm mutant suspended in 10 µL of PBS. For WT S. canis strain G361
and ∆scm competition experiments, mice were vaginally inoculated with 1 × 107 CFU
each of G361 and ∆scm suspended in 10 µL of PBS. Colonization was monitored daily
by collecting vaginal swabs (Puritan, Cat. # 25-801 A 50). Bacterial load was determined
by serial dilution plating on CHROMagar™ StrepB base (DRG International Inc) and
where necessary, WT G361 and ∆scm distinguished by plating on CHROMagar containing
erythromycin (5 µg/mL).
2.14. Flow Cytometry
Vaginal swab samples obtained during swabbing for bacterial colonization were
subjected to flow cytometry as adapted from previous work [36,41]. Vaginal lumen cells
were released from vaginal swabs by vortexing for 2–3 s, passed through a 40-µm-pore-size
filter, and pelleted at 500× g for 5 min. Cells were blocked with 1:200 mouse BD Fc-block
(BD Biosciences) for 15 min on ice in 50 µL of PBS containing 1 mM EDTA, 1% FBS, and
0.1% sodium azide. Cells were stained for surface markers using the following antibodies
at 5µg/mL for 30 min on ice: anti-CD11b-fluorescein isothiocyanate (FITC) (clone M1/70,
catalog no. 553310; BD Pharmingen), anti-c-kit-phycoerythrin (PE) (clone 2B8, catalog no.
1880-09; Southern Biotech), anti-CD8-PerCP-Cy5.5 (where PerCp is peridinin chlorophyll
protein) (clone 53–6.7, catalog no. 100734; Biolegend), anti-F4/80-PE-Cy7 (clone BM8,
catalog no. 123114; Biolegend), anti-Ly6G-allophycocyanin (APC) (clone 1A8, catalog no.
127614; BioLegend), anti-MHC-II-APC-Fire750 (clone M5/114.15.2, catalog no. 107652;
BioLegend), anti-FcεRI-Pacific Blue (clone MAR-1, catalog no. 134313; BioLegend), and
anti-CD45-BV510 (clone 30-F11, catalog no. 103138; BioLegend). Samples were washed
3X in PBS containing 1 mM EDTA, 1% FBS, and 0.1% sodium azide. Samples were run on
a BD FACSCanto II (BD Biosciences), were gated on unstained cells, and positive signals
were determined using single-stain controls. Data were analyzed with FlowJo, version 10.2,
software (FlowJo LLC).
2.15. Tissue Histology
Whole reproductive tract tissues were collected at day 3 post-inoculation, fixed in 10%
neutral buffered formalin for 24 h, and dehydrated by an ethanol gradient and embedded
in paraffin. Tissue sectioning and hematoxylin and eosin (H&E) staining was performed by
the UC San Diego Comparative Phenotyping Core. H&E-stained slides were examined for
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presence and character of inflammation by an ACVP board-certified veterinary anatomic
pathologist. Representative images were captured using a Leica brightfield microscope
and color CCD camera.
2.16. Statistical Analyses
In vitro and ex vivo experiments were repeated at least three times independently
with at least three technical replicates with the exception of human serological studies
which were performed in technical duplicate and analyzed twice independently. Mean
values from independent experiments were used to represent biological replicates for
statistical analyses. In vivo experiments were conducted at least twice independently
which each mouse serving as a biological replicate. Experimental data was combined
prior to statistical analyses. Data sets were subjected to D’Agostino & Pearson normality
test to determine Gaussian distribution before selecting the appropriate parametric or
non-parametric analyses. In instances where experimental numbers (n) were too small
to determine normality (Figure 1C, Figure 2A,C–F, Figure 3A,B and Figure 4A–C,E) data
were assumed non-parametric. Analyses include parametric test two-way ANOVA with
Sidak’s multiple comparisons post-test, and non-parametric tests including Kruskal Wallis
test with Dunn’s multiple comparisons post-test, Friedman test with Dunn’s multiple
comparisons test, Wilcoxon matched-pairs signed rank test with Spearman rank-order
correlation, and Log-rank (Mantel-Cox) test as indicated in figure legends. Statistical
analyses were performed using GraphPad Prism, version 8.4.3 (GraphPad Software Inc.,
La Jolla, CA, USA). p values < 0.05 were considered statistically significant.
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condition) of S. canis G361 or G361Δscm biofilms grown for 48 h in THB or RPMI and stained with SYTO 13. Symbols 
represent individual experimental replicates (A–C) with lines indicating interquartile ranges. Representative images are 
of independent experimental replicates, scale bar = 200 μm (D). Data were analyzed by two-way ANOVA with Sidak’s 
multiple comparisons post-test (A–C). *, p < 0.05. 
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The M-protein of S. pyogenes contributes to resistance of host immune cell-mediated 
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line DH82, we observed no differences in bacterial killing (Figure 2A) or induction of re-
active oxygen species (Figure 2B) between WT and SCM-deficient S. canis. Using the hu-
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cell control of WT and SCM-deficient S. canis, or S. pyogenes WT strain 5448 (Figure 2C). 
Since S. pyogenes M-protein activates the NLRP3 inflammasome [38], we measured levels 
of activated IL-1β released by infected THP-1 cells using an IL-1β HEK-Blue reporter cell 
assay. Although WT 5448 infection induced twice as much active IL-1β compared to iso-
genic Δemm1 as observed previously [38], we detected no difference in IL-1β induction 
between the WT G361 and Δscm conditions, and levels were similar to that induced by the 
Δemm1 strain (Figure 2D). 
Figure 1. SCM deficiency minimally impacts S. canis growth, hemolytic activity, and biofilm formation. Growth curves
of S. canis G361 or G361∆scm in Todd-Hewitt broth (THB, (A)) or RPMI-1640 (RP I, (B)) as measured by optical density
(OD60 ). ( ) i fil f r ti f . c is r ∆sc r r 5448∆e i T or RP I quantified by
SYT 13 fluorescence and expres ed as the percent fluorescence of the WT strain. (D) Representative images (two per
condition) of S. canis G361 or G361∆scm biofil s grown for 48 h in THB or RPMI and stained with SYTO 13. Symbols
represent individual experi ental replicates (A–C) with lines indicating interquartile ranges. Representative i ages are
of independent experimental replicates, scale bar = 200 µm (D). Data were analyzed by two-way ANOVA with Sidak’s
multiple comparisons post-test (A–C). *, p < 0.05.
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activity in human sera. (A) Percent survival of S. canis G361 or G361∆scm after 30 min of exposure to canine DH82
macrophages, MOI = 1. (B) Reactive oxygen species production by DH82 macrophages infected with S. canis G361 or
G361∆scm, MOI = 10, and normalized to uninfected cells. (C) Percent survival of S. canis G361 or G361∆scm after 30 min
of exposure to human THP-1 differentiated macrophages, MOI = 1. (D) THP-1 cells were infected with S. canis G361
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calculated versus GAS across four independent experiments. (E) Percent survival of S. canis G361 or G361∆scm after 30 or
60 min of infection in human whole blood. (F) Percent survival of S. canis G361 or G361∆scm after 30 or 60 min of infection
in isolated human neutrophils, MOI = 1. (G) Quantification of human IgG titers, expressed as relative fluorescent units
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signed rank test (A), two-way ANOVA with Sidak’s multiple comparisons post-test (B,E,F), or Friedman test with Dunn’s
multiple comparisons test (C,D) and determined not significant.
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in these models. (A) Percent survival of S. canis G361 or G361∆scm after 30 min of infection in murine whole blood collected
from CD1 mice. (B) CD1 male and female mice were infected subcutaneously with 1× 108 CFU of WT S. canis G361 or
G361∆scm and skin lesion size measured daily. (C) Representative image of skin lesions three days post subcutaneous
infection with WT S. canis G361 (left) or G361∆scm (right). (D) CD1 male and female mice were infected intraperitoneally
with 5 × 107 CFU of WT S. canis G361, G361∆scm, or S. pyogenes 5448 and survival monitored over 3 days. Symbols
represent biological replicates ((A), n = 5/group, (B), n = 20/group, and (D), n = 10-21/group) with lines indicating medians
and interquartile ranges (A,B) or percentage survival (D). Data were analyzed by Wilcoxon matched-pairs signed rank test
(A), two-way ANOVA with Sidak’s multiple comparisons post-test (B) or Log rank Mantel-Cox test (D) and determined
not significant.
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Figure 4. S. canis adheres to vaginal epithelial cells and persists in a murine model of vaginal colonization, and SCM
confers a fitness advantage in this environment. (A) Percent adherence of S. canis G361, G361∆scm, or GBS COH1 to VK2
cells after 30 min of infection, MOI = 1. CD1 female mice were vaginally administered 1 × 107 CFU of WT S. canis G361,
G361∆scm, or WT GBS COH1, or PBS as a control. (B) Mice were vaginally swabbed daily, and the levels of bacterial CFU
recovered from swabs are shown. (C) Cells collected from day 3 post-inoculation were analyzed for surface markers via flow
cyt metry. Total cell counts of each populati n recovered n the swabs are shown. (D) Vaginal epithelial tissues were fixed,
sectioned, and staine with H&E. Histological examination revealed ker tiniz d epith lium (top i ages) and neutrophil
infiltration (bottom images) si ilarly across treatment groups. Magnification = 200X. (E) CD1 female mice were vaginally
administered 1 × 107 CFU each of WT S. canis G361 and G361∆scm in competition. Mice were vaginally swabbed daily,
and the levels of bacterial CFU recovered from swabs are shown. Symbols represent biological replicates ((B), n = 18/group,
(C), n = 12–18/group, and (E), n = 20/group) or the means of four independent experimental replicates (B), performed in
technical duplicate) with lines indicating medians and interquartile ranges. Dotted line in (B,E) indicates limit of detection.
Data were analyzed by Kruskal-Wallis test with Dunn’s multiple comparisons test (A), two-way ANOVA with Sidak’s
multiple comparisons post-test (B,C) or Wilcoxon matched-pairs signed rank test (E). ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns,
not significant.
3. Results
3.1. SCM Deficiency Minimally Impacts S. canis Growth, Biofilm Formation, Hemolytic Activity,
and Sensitivity to Aminizing and Oxidizing Agents
The -protein is a well-characterized virulence factor of S. pyogenes, and the or-
thologous nature of the SCM protein suggests a potential for a similar role in S. canis
pathogenesis. To investigate the role of SCM in S. canis virulence, we utilized a SCM inser-
tional mutant made from the S. canis G361 clinical isolate strain that no longer produces
the SCM protein and exhibits reduced aggregate formation in culture [32]. We confirmed
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that loss of SCM did not alter in vitro growth of S. canis compared to wildtype S. canis
in bacteriologic media (THB, Figure 1A) or tissue culture media (RPMI-1640, Figure 1B).
Since M protein types have been associated with biofilm formation in S. pyogenes [42], we
assessed the contribution of SCM to biofilm formation in S. canis. No differences in biofilm
formation between WT G361 and ∆scm were observed in RPMI-1640 media, however, in
THB media, mutant strains had decreased biofilms relative to WT as detected by fluo-
rescence (Figure 1C). This finding mirrored what was observed in S. pyogenes 5448 and
∆emm1. Microscopically, WT G361 formed similar biofilms in THB and RPMI-1640 media,
however, ∆scm displayed decreased bacterial aggregation in RPMI-1640 compared to WT
G361 (Figure 1D). Loss of SCM did not impact beta-hemolytic activity on blood agar (Figure
S1). Sensitivity to aminizing or oxidizing agents (hypochlorite and hydrogen peroxide,
respectively) was not decreased due to SCM-deficiency (hypochlorite MIC: 0.26 mM and
hydrogen peroxide MIC: 0.83 mM for both strains in three independent experiments).
3.2. SCM Does Not Contribute to S. canis Survival, Reactive Oxygen Species Release, or Cytokine
Production in Macrophages
The M-protein of S. pyogenes contributes to resistance of host immune cell-mediated
killing [43,44]. To investigate if the SCM protein of S. canis shares these immunomodulatory
functions, we conducted bacterial killing and immune response assays in vitro using a
variety of immune cell lines as well as whole blood. Using the canine macrophage cell
line DH82, we observed no differences in bacterial killing (Figure 2A) or induction of
reactive oxygen species (Figure 2B) between WT and SCM-deficient S. canis. Using the
human monocyte cell line THP-1, we observed no differences between differentiated THP-1
cell control of WT and SCM-deficient S. canis, or S. pyogenes WT strain 5448 (Figure 2C).
Since S. pyogenes M-protein activates the NLRP3 inflammasome [38], we measured levels
of activated IL-1β released by infected THP-1 cells using an IL-1β HEK-Blue reporter
cell assay. Although WT 5448 infection induced twice as much active IL-1β compared to
isogenic ∆emm1 as observed previously [38], we detected no difference in IL-1β induction
between the WT G361 and ∆scm conditions, and levels were similar to that induced by the
∆emm1 strain (Figure 2D).
3.3. SCM Deficiency Does Not Alter S. canis Susceptibility to Human Whole Blood and
Neutrophils nor Is SCM Antisera Detected in Healthy Human Samples
To assess S. canis virulence in more clinically relevant conditions, we gauged survival
of S. canis exposed to human whole blood or purified neutrophils isolated from peripheral
human blood. We did not detect any differences between WT G361 and ∆scm survival in
whole blood, and recovered greater than 100% of the bacterial inoculum in the majority of
donors suggesting S. canis is not readily killed in human blood (Figure 2E). Additionally,
we did not observe any differences in WT G361 and ∆scm exposed to primary human
neutrophils (Figure 2F), although bacterial survival across conditions was <10%, suggesting
human neutrophils demonstrate more potent killing than either the canine or human
monocyte/macrophage cells lines (Figure 2A,C). The S. pyogenes M proteins are widely
recognized as immunodominant antigens [45], and feline antisera against SCM has been
reported [46]. To investigate whether anti-SCM IgG titers are present across healthy human
donors, we screened 20 human donors for IgG binding to a purified truncated form of SCM
(KO173225) [31] which does not bind human IgG Fc. Human recombinant IgG immobilized
on the microtiter plates was used as a positive control. Bound IgG was only detected at
1:100 serum dilutions and did not achieve the level of the positive controls at any dilution,
suggesting signal is likely due to background (Figure 2G).
3.4. S. canis Is Highly Virulent in Mouse Models of Systemic and Dermal Infection, yet SCM Does
Not Contribute to Virulence in These Models.
Since in vitro assays do not fully reflect complex host-microbe interactions, and thus
might not be sensitive enough to assess the subtler contributions of SCM to S. canis viru-
lence, we undertook mouse models of invasive disease. Initial studies with murine whole
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blood revealed no differences between WT G361 and ∆scm survival, and we recovered
more than 200% of the bacterial inoculum in the majority of samples suggesting S. canis is
not readily killed in mouse blood (Figure 3A). To interrogate whether SCM contributes to
S. canis virulence in soft tissue infection, CD1 mice received intradermal injection of 1× 108
CFU of WT G361 or ∆scm and lesion size monitored over 3 days. Although both WT G361
and ∆scm led to visible formation of skin lesions, no difference in lesion size was observed
at any time point (Figure 3B,C). To assess whether SCM contributes to S. canis morbidity in
systemic infection, CD1 mice received intraperitoneal injection with 5 × 107 CFU of WT
G361, ∆scm, or WT S. pyogenes 5448 and mortality monitored over 3 days. Infection with
WT G361 or ∆scm resulted in rapid decline with 100% mortality by 18 h post-infection. In
contrast, S. pyogenes 5448 exhibited slower mortality although not statistically significant
(p = 0.096, Figure 3D).
3.5. S. canis Adheres to Vaginal Epithelial Cells and Persists in a Murine Model of Vaginal
Colonization, and SCM Confers a Fitness Advantage in This Environment
S. canis is commonly isolated from the urogenital tract of dogs [47], and the G361
strain used in these studies was originally isolated on a vaginal swab from a woman who
suffered premature membrane rupture during pregnancy [33]. Since the majority of S. canis
strains are SCM positive [3], we hypothesized that the SCM protein may provide a fitness
advantage to S. canis in the urogenital tract. To study the potential role of SCM in vaginal
colonization, we first assessed the adherence of WT G361 or ∆scm to immortalized human
vaginal epithelial cells (VK2) and included a strain of the common vaginal colonizing
bacterial species group B Streptococcus (GBS) as a comparison. Although no differences in
vaginal cell adherence was observed between WT G361 and ∆scm, both S. canis isolates
adhered significantly better than GBS (p = 0.016 and 0.048 respectively, Figure 4A).
To assess whether SCM contributes to S. canis vaginal persistence in vivo, we estab-
lished a novel mouse model of vaginal colonization using the wildtype and SCM mutant
strains of the G361 isolate. Adapted from previous mouse models of GBS vaginal colo-
nization [40], female CD1 mice were synchronized for estrous stage, and inoculated with
a single vaginal dose of 1 × 107 CFU of WT G361, ∆scm, or GBS, and bacterial burdens
monitored via vaginal swabbing daily for 3 days. Mice inoculated with WT G361 exhibited
significantly higher bacterial burdens than ∆scm (p = 0.013) or GBS (p = 0.003) on day 1 post-
inoculation, but no significant differences were seen in subsequent time points (Figure 4B).
To determine if S. canis induced a local vaginal immune response, cells recovered from day
3 swabs from WT G361, ∆scm, or PBS-inoculated control mice were stained and analyzed
via flow cytometry with antibodies for the following cell surface markers: CD45, CD11b,
CD8, major histocompatibility complex class II (MHC-II), F4/80, Ly6G, FcεRI, and c-kit.
CD45+ cells were analyzed for the presence of additional surface markers and total cell
counts of each sub-category were reported. CD8+ T cells (CD45+ CD8+), mast cells (CD45+
c-kit+ FcεRI+), macrophages (CD45+ CD11b+ F4/80+), neutrophils (CD11b+ Ly6G+), and
antigen presenting cells (CD11b+/- MHC-II+) were all observed, but numbers did not
significantly differ across groups (Figure 4C). Additionally, we collected reproductive
tract tissues at day 3 post-inoculation. Histological examination of the vaginal epithelium
showed a range of appearances consistent with estrus (keratinized epithelium, Figure 4D,
top images) or metestrus (neutrophil infiltration, Figure 4D, bottom images), no differences
were observed across treatment groups. To determine whether SCM-deficiency confers a
disadvantage to S. canis vaginal colonization, female CD1 mice were vaginally inoculated
with equal amounts of WT G361 and ∆scm (1 × 107 CFU of each) and bacterial burdens
quantified over 3 days via vaginal swab. WT G361 and ∆scm were differentiated by plat-
ing on agar with and without erythromycin. In competition, ∆scm showed significantly
lower burdens than WT G361 on days 2 and 3 post-inoculation. To confirm that the ∆scm
mutant was not losing the plasmid insertion in vivo over time, we assessed the stability
of erythromycin resistance in CD1 mice singly challenged with ∆scm by plating on both
selective and non-selective agar plates. No differences were observed in bacterial counts
using either erythromycin selection or no selection (Figure S2).
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4. Discussion
S. canis is a well-known pathogen of dogs, cats, and other mammals, and an oppor-
tunistic zoonotic disease of humans [48–52], yet molecular factors promoting colonization
and virulence are poorly understood. SCM is hypothesized to have similar roles as the
diverse M-like proteins of other streptococcal species in the context of pathogenesis and
immune evasion. To this point, multiple studies demonstrate SCM interactions with host
proteins [29,31,53]; however, to date, studies have not investigated the role that SCM plays
in pathogenesis and colonization in vivo. Our work seeks to bridge this gap in knowledge
and define the importance of SCM in epithelial and immune cell interactions in vitro and
in novel mouse models of S. canis pathogenesis and colonization. Overall, we observed
minimal contributions of SCM to S. canis interactions with the host in either commensal
or pathogen contexts using the S. canis strain G361 which possesses a SCM type 2, group
1 allele [12]. Importantly, it remains possible that SCM proteins belonging to different
group alleles may differentially impact S. canis interactions with its host. Prevalence of
SCM in veterinary S. canis isolates is quite high: both colonizing and invasive isolates are
70.6-90.0% SCM positive by PCR [3,54] suggesting possible biological pressure(s) to retain
SCM for successful S. canis colonization and/or invasive disease.
In terms of bacterial characteristics, SCM is non-essential for growth, either in nutrient-
rich bacteriologic media or nutrient-poor tissue culture media. SCM also does not con-
tribute to hemolysis in S. canis, similar to reports for other streptococcal M-like proteins [55].
In S. pyogenes, M1 over-expression enhances biofilm formation and M1-deficient strains
demonstrated reduced biofilm formation in bacteriologic media [42]. Similarly, we noted
decreased biofilm formation in SCM-deficient S. canis in bacteriologic media, however,
this finding was not observed in conditions reflective of the host environment (RPMI,
Figure 1C). In S. pyogenes, M protein contributes to the hydrophobicity of the bacterial
surface, leading to greater biofilm formation [42]. Thus, loss of SCM in S. canis possibly
reduces surface proteins with greater hydrophobicity, leading to the observed decrease in
biofilm formation. Alternatively, because SCM activity is associated with S. canis aggrega-
tion microcolony formation in vitro [56], loss of homophilic interactions between SCM in
the ∆scm strain may alter the morphology of S. canis biofilms [32,57]. In fact, although there
was no difference in the relative fluorescent units (RFU) of WT G361 and ∆scm biofilms in
RPMI-1640, the morphology of the biofilms was visibly different. While WT G361 biofilms
grown in RPMI-1640 formed microcolonies comparable to WT G361 grown in THB, ∆scm
grown in RPMI-1640 formed diffuse biofilms with fewer microcolonies (Figure 1D). The
impact of this altered biofilm morphology on S. canis interactions within different host
tissues is a topic of future study.
Streptococcal M proteins play key roles in virulence and host immune evasion.
S. pyogenes M proteins confer resistance against phagocytosis by inhibiting the alter-
nate complement pathway [58,59], or alternatively, through forming bacterial aggregates
with self [56,60] or as a complex with host cells [61,62]. Similarly, in S. canis, this self-
aggregation is lost in the absence of SCM [32]. However, in our assays with canine or
human macrophage cell lines, we found that presence of SCM did not alter macrophage-
mediated killing of S. canis (Figure 2). In fact, neither WT or ∆scm bacteria were effectively
controlled by macrophage cell lines or human and mouse whole blood, with ~100% or
more of inoculum recovered at the experimental end point. This contrasts our findings with
isolated human neutrophils, which efficiently reduced S. canis viability by more than 90%
over the assay (Figure 2F), yet with no significant contribution of SCM to S. canis neutrophil
resistance. This observation is in line with a previous study which did not observe any
differences in neutrophil control of SCM-positive or SCM-negative S. canis except for when
exogenous SCM and/or plasminogen was present [57].
Another notable activity of M-like proteins is resistance to host immune defense
molecules and activation of innate inflammatory responses, best characterized in S. pyo-
genes. S. pyogenes M1 neutralizes cathelicidin [30,34], stimulates neutrophil recruitment
and myeloperoxidase release [63], and activates the NLRP3 inflammasome triggering
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IL-1β-dependent pyroptosis in macrophages [38]. In our in vitro immune cell models,
we observed no differences in reactive oxygen species (ROS) production or induction of
IL-1β between SCM-deficient and wildtype S. canis (Figure 2). Overall, we observed only
modest induction of ROS, and minimal induction of IL-1β in macrophages infected with
S. canis with levels similar to that of M protein-deficient S. pyogenes. This failure to elicit
an immune response could benefit S. canis as it avoids the production of inflammatory
cytokines and pyroptosis that have been shown to be critical for the control of some bacte-
rial pathogens [64]. However, in our in vivo models of S. canis invasive infection, we did
not distinguish distinctive contributions of SCM. No differences in skin lesion sizes were
observed between SCM-deficient and WT S. canis, and in general, we observed smaller
lesion sizes than that reported for a similar model in S. pyogenes [30]. Time points beyond 3
days were not assessed in our studies. We observed high lethality of S. canis compared to
S. pyogenes in a murine model of systemic infection at a dose of 5 × 107 CFU, similar to a
previous study, which demonstrated an LD90 of 3 × 107 CFU in mice [28].
Additionally, the antigenic nature of S. pyogenes M proteins is well-recognized [65,66],
and anti-M protein responses are associated with host protection against repeat infection
by strains of the same M type [67,68]. Regarding S. canis, antisera against SCM has been
detected in diseased cats [46]. No compelling evidence for SCM anti-sera in healthy human
donors was detected in our cohort, however, subjects with known active or prior S. canis
infections or exposure were not included in this study.
Along with relevance to pathogenesis, streptococcal M proteins play prominent roles
in host colonization. This phenomenon may be in part due to mediating adherence [69],
although M proteins may not necessarily promote adhesion to all epithelial types [56], and
expression of certain M proteins may even reduce epithelial adherence [70]. Although we
observed no contribution of SCM in adherence to human vaginal epithelial cells in vitro,
it is possible that these cells do not produce the same extracellular matrix or surface
proteins to recapitulate in vivo conditions. Furthermore, we observed a striking increase is
S. canis adherence to VK2 compared to the frequently isolated vaginal bacterium group
B Streptococcus (Figure 3) [71,72] but the underlying molecular basis for this heightened
adherence is currently unknown. In vivo, S. canis persisted in the mouse vaginal tract at
similar levels to GBS highlighting the utility of this murine model in studying S. canis
factors contributing to urogenital colonization. We detected no changes to immune cell
profiles or epithelial appearance suggesting that S. canis does not stimulate a robust vaginal
immune response soon after introduction. This contrasts with other human pathogen
vaginal colonization models which do invoke immune responses [72–74] and may reflect
the primarily colonizing role for S. canis in mammals such as cats and dogs. Although
we observed minimal contribution of SCM in S. canis colonization in a single bacterial
challenge model, when both WT S. canis and ∆scm were introduced in competition, WT
S. canis demonstrated a competitive advantage (Figure 4E). The underlying mechanisms
for this SCM-mediated advantage in niche establishment are unknown, but this finding
provides rationale for the conservation and heterogenetic variability of SCM across clinical
isolates [12,23].
In summary, we have deployed several new in vitro and mouse models of S. canis
infection and colonization and interrogated the role of SCM in these models using a
targeted knockout mutant. We observed minimal impact of SCM deficiency in invasive
disease models, but found an SCM-associated advantage in vaginal colonization. These
results suggest that the role of SCM is distinct from the repertoire of virulence mechanisms
ascribed to other streptococcal M proteins. Further studies are necessary to determine the
mechanisms underlying decreased colonization fitness of SCM-deficient S. canis and to
extend our findings to other SCM variants. Identification of these mechanisms will provide
insight into the viability of SCM as a vaccine target for the zoonotic pathogen S. canis.
Supplementary Materials: The following are available online at https://www.mdpi.com/2076-2
607/9/1/183/s1, Figure S1: SCM has no effect on hemolytic activity; Figure S2: SCM insertional
mutagenesis is stable in vivo.
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